DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). Its aim is to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. The company was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France. DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.
Biotechnology, Life Science, healthcare
Between €2.5 million-5 million
💡 You’re a corporate or investor and looking for startups that are innovating in the same market as DiogenX? We’re happy to assist you with our Startup Sourcing service.